Pathoquest
Paris, FR · Founded 2010 · 60 employees on LinkedIn · 2 known investors
Find your way into Pathoquest
Sign up to see every warm intro you have to Pathoquest
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pathoquest team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PathoQuest develops iDTECT, a platform of Next Generation Sequencing (NGS) assays for biopharmaceutical quality control, offering animal-free viral safety testing and genetic characterization of cell banks and biologics. The company was acquired by Charles River Labs to expand its end-to-end biologics testing portfolio.
Founders & leadership
Pathoquest was founded in 2010 by Marc Eloit.
Investors · 2
Frequently asked questions
- What does Pathoquest do?
- PathoQuest develops iDTECT, a platform of Next Generation Sequencing (NGS) assays for biopharmaceutical quality control, offering animal-free viral safety testing and genetic characterization of cell banks and biologics. The company was acquired by Charles River Labs to expand its end-to-end biologics testing portfolio.
- Who founded Pathoquest?
- Pathoquest was founded by Marc Eloit in 2010.
- Who are Pathoquest's investors?
- Pathoquest's investors include Kurma Partners, Verve Ventures.
- Where is Pathoquest headquartered?
- Pathoquest is headquartered in Paris, FR.


.jpeg)